EQT has launched a voluntary public takeover offer for QIAGEN, the molecular diagnostics group, at 46.50 euros in cash per share, with the Abu Dhabi Investment Authority and CPP Investments joining as co-investors.
The offer was announced on 21 October 2026. The bidder is Crown NL Bidco, an Amsterdam holding company controlled indirectly by EQT XI, a fund managed by affiliates of EQT. The offer covers all issued ordinary shares of QIAGEN and is subject to a minimum acceptance threshold of 50 per cent of the outstanding share capital plus one share.
The two co-investors come in through wholly owned subsidiaries. Luxinva is the vehicle for the Abu Dhabi Investment Authority, and CPP Investment Board Europe is the vehicle for CPP Investments. Both are sovereign and pension capital of the kind that has increasingly sat alongside private equity on large take-private transactions, where the equity cheque is too big for a single fund to write comfortably and the holding period is expected to run long.
The management board and the supervisory board of QIAGEN have agreed, under a business combination agreement, to support the offer fully and to recommend it to shareholders for acceptance. That is a negotiated recommended offer rather than a hostile approach, which materially changes the probability of completion even at a 50 per cent plus one threshold.
Closing is currently expected in the middle of next year. That is a long runway by the standards of a recommended cash offer, and it reflects the antitrust and foreign investment clearances a diagnostics business of this footprint attracts across Europe, the United States and Asia.
A figure of about 10.8 billion dollars for the aggregate value of the transaction has circulated widely in secondary coverage. It does not appear in the offer announcement itself, which states the price per share and the acceptance threshold and leaves the aggregate to be inferred, so it is reported here as a market estimate rather than as a disclosed number.
QIAGEN has been the subject of takeover interest before, and the approach lands at a point when listed diagnostics companies have traded well below their pandemic-era ratings while their installed instrument bases and consumables annuities have held up. That gap between public market rating and cash generation is the pattern the large buyout funds have been working through the healthcare tools sector, and it is why sovereign and pension co-investors have been willing to take the duration risk alongside them.
Neither EQT nor QIAGEN disclosed the financing structure behind the cash component, and no break fee was stated in the announcement.
